Evidence-Based Management of Urinary Tract Infections: Balancing Efficacy, Safety, and Antimicrobial Stewardship

 

Fadilullahi Opeyemi Ibiyemi¹*, Deborah Awoniran², Anthony Godswill Imolele², Ismail Kolawole Odetayo³, Lawal Fatimah Ayomide³

 

1. Department of Chemistry & Industrial Chemistry, Osun State Water Regulatory Commission, Ministry of Water Resources, Osun State, Nigeria

2. Miami University Ohio, Zip code: 45056-1846, United State of America; Ambrose Alli University, Ekpoma, 310104, Edo, Nigeria

3. Department of Biochemistry & Industrial Chemistry Fountain University, P.M.B. 4491 Osogbo Osun State, Nigeria; Babcock University, Ogun State, Nigeria

 

*Correspondence: ibiyemi.ademola97@gmail.com;

DOI: https://doi.org/10.71431/IJRPAS.2025.41003

Article Information		Abstract
Review Article Received: 22/09/2025 Accepted: 22/10/2025 Published: 31/10/2025   Keywords Fluoroquinolones; Beta-Lactams; Aminoglycosides; Carbapenems; Antimicrobial Resistance; UTI Management		Urinary tract infections (UTIs) are some of the most prevalent infectious diseases around the globe, affecting about 150 million people every year and putting a considerable strain on healthcare systems, both financially and clinically. This comprehensive review takes a closer look at the current landscape of UTI treatment, shining a light on first-line antimicrobial agents like nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin, as well as alternative options such as fluoroquinolones, beta-lactams, aminoglycosides, and carbapenems. The review dives into how these treatments function, their effectiveness, and the emerging patterns of resistance, particularly the growing concern of antimicrobial resistance in common uropathogens, especially Escherichia coli. While there are established guidelines recommending specific first-line therapies, a noticeable gap remains between the evidence and what actually occurs in clinical practice, with fluoroquinolones like ciprofloxacin often being overprescribed for uncomplicated infections. The rising presence of multidrug-resistant organisms, such as extended-spectrum beta-lactamase-producing Enterobacterales, necessitates a careful reassessment of treatment strategies and a commitment to antimicrobial stewardship. With resistance rates exceeding 50% in certain regions for commonly used antibiotics, there's an urgent need for innovative treatment strategies, enhanced surveillance systems, and responsible antibiotic use to preserve the effectiveness of current therapies and address the escalating threat of antimicrobial resistance in managing UTIs.

 

INTRODUCTION

Urinary tract infections (UTIs) are a common type of microbial infection that can affect any part of the urinary system, including the ureters, kidneys, bladder, and urethra. These infections range from mild cases of cystitis to severe uroseptic shock, making them one of the most widespread infectious diseases globally. Each year, around 150 million people are affected¹,². This widespread issue brings with it a significant economic and clinical burden, leading to millions of emergency room visits and hospitalizations every year³,⁴. The financial impact is substantial, with estimates suggesting that the costs in the United States alone could reach several billion dollars annually due to healthcare expenses, medications, and lost productivity⁵,⁶. Globally, UTIs account for about 3 million health service visits each year, and in more complicated cases, they can lead to serious complications like renal failure and sepsis⁷.

The prevalence of urinary tract infections is particularly high among certain groups, with nearly 50% of women experiencing at least one UTI in their lifetime. Additionally, UTIs are the second most common infection found in hospital patients over the age of 65⁸,⁹. While bacterial pathogens, especially uropathogenic Escherichia coli, are the primary culprits, other pathogens such as fungi and some viruses can also cause these infections²,¹⁰. The interplay between host defense mechanisms and microbial virulence factors, like the bacteria's ability to adhere to uroepithelial cells and form biofilms, is crucial in the development and persistence of UTIs¹¹.

FIRST-LINE ANTIBIOTICS (Nitrofurantoin, Trimethoprim-Sulfamethoxazole, Fosfomycin)

First-line antibiotics are the go-to medications for treating bacterial infections. They're selected based on a mix of empirical data, local resistance patterns, and individual patient factors to ensure the best outcomes. The aim is to target the most likely pathogens effectively while minimizing the risk of developing antimicrobial resistance¹². For instance, when managing uncomplicated urinary tract infections, the most commonly prescribed first-line antibiotics include nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin trometamol, typically for short courses lasting between one to seven days¹³.

However, despite these guidelines, some doctors still prescribe fluoroquinolones like ciprofloxacin for urinary tract infections, even though they aren't the first choice. This suggests a disconnect between what the guidelines recommend and what is actually prescribed¹⁴. The frequent use of broad-spectrum antibiotics like fluoroquinolones for uncomplicated infections is a significant contributor to the global issue of antimicrobial resistance¹⁵. This practice often arises from an empirical prescribing approach in the face of increasing resistance rates, even when guidelines suggest more targeted treatments¹⁴. The rising resistance, particularly among common uropathogens like Escherichia coli, to widely used antibiotics such as ciprofloxacin and third-generation cephalosporins highlights the urgent need to reevaluate empirical treatment strategies¹⁶. This underscores the importance for clinicians to adhere closely to established guidelines and consult local antibiograms when making informed decisions about first-line therapies¹⁴.

 

 

NITROFURANTOIN

Nitrofurantoin is a synthetic antimicrobial derived from nitrofuran, and it's often prescribed due to its ability to both inhibit and kill bacteria that cause urinary tract infections. It works by blocking various enzymatic processes in bacteria, including those needed for synthesizing DNA, RNA, and proteins, thanks to a reduction reaction involving their flavoproteins¹⁷. One of the reasons it remains effective after many years on the market is its unique mechanism of action, which helps prevent bacteria from developing resistance¹⁸. Unlike many other antimicrobial drugs that face resistance through single-point mutations, nitrofurantoin targets multiple bacterial functions, making it harder for bacteria to adapt¹⁹.

While nitrofurantoin has well-known applications for treating urinary tract infections, the workings of hydantoin-derived antimicrobials are more complex and not fully understood. They likely involve several factors, including interactions with bacterial DNA repair mechanisms and ribosome binding²⁰. Recent research indicates that hydantoin-type derivatives, especially those with cationic groups and fatty chains, exert their antibacterial effects by damaging membranes, similar to how host defense peptides work, rather than just inhibiting DNA damage²⁰. This new approach of targeting membranes not only provides direct bactericidal action but also helps prevent resistance in tough pathogens like methicillin-resistant Staphylococcus aureus²⁰.

Nitrofurantoin (NF) is a redox-active antibacterial agent with the chemical formula C8H6N4O5 and a molecular weight of 238.16. It's an oral antibiotic derived from nitrofurans²¹. When food is present in the gastrointestinal (GI) tract, it tends to slow down gastric emptying, which means that more NF can dissolve in gastric juice before it makes its way to the duodenum²². NF is effective against a variety of bacteria, including Gram-positive ones like Staphylococcus and Enterococcus, as well as Gram-negative bacteria such as Klebsiella and Citrobacter²³. The nitro group in its structure interacts with cytochrome P450 reductase, impacting protein synthesis and ribosomal function in susceptible bacteria²⁴, and it disrupts the Krebs cycle by inhibiting several enzymes involved in carbohydrate metabolism²⁵,²³, along with affecting cell walls and DNA.

While NF is generally considered a safe antimicrobial drug, there are some risks associated with long-term use, affecting about 1 in 100,000 patients²⁶. Side effects unrelated to drug resistance, such as hepatotoxicity, neuropathy, and pulmonary damage, can arise from prolonged use²⁴. Three notable complications include gastrointestinal issues, skin reactions, and peripheral neuropathy²⁷.

TRIMETHOPRIM-SULFAMETHOXAZOLE

Co-trimoxazole, commonly known by its generic name, is a powerful combination of antimicrobial agents that plays a crucial role in our toolkit for tackling a wide variety of bacterial infections. It works by sequentially blocking folate synthesis, which is a vital metabolic pathway that bacteria need for growth and reproduction²⁸. Specifically, sulfamethoxazole inhibits dihydropteroate synthase, while trimethoprim targets dihydrofolate reductase, effectively blocking two key enzymatic steps necessary for bacteria to produce DNA²⁹. This dual action not only boosts the antimicrobial effectiveness of the combination but also helps slow down the development of bacterial resistance compared to using either drug alone³⁰. By inhibiting two different pathways, this combination disrupts bacterial replication and often makes the bacteria more susceptible to our immune defenses. However, it's important to note that trimethoprim can lead to folate deficiency in host cells, particularly in individuals who already have low levels, as it inhibits the function of the host's dihydrofolate reductase³¹.

According to Wormser et al.³², Co-trimoxazole, which combines trimethoprim and sulfamethoxazole, is a broad-spectrum antimicrobial that shows effectiveness in vitro against a wide array of microorganisms. This medication has been in clinical use for over ten years across various countries. While it's mainly known as the go-to treatment for Pneumocystis carinii infections, it also proves beneficial for a host of other infectious diseases. These include both acute and recurrent urinary tract infections (for treatment and prevention), ear, nose, and throat infections (even those caused by β-lactamase-producing H. influenzae), acute flare-ups of chronic bronchitis, enteric fever, gonorrhea, and neutropenia prophylaxis, along with several other uses that are not as firmly established.

Co-trimoxazole is effective against a diverse range of organisms, such as Gram-positive and Gram-negative aerobic bacteria, chlamydia, Nocardia, some mycobacteria, protozoa, and many anaerobic bacteria. However, it doesn't work against Mycobacterium tuberculosis, Treponema pallidum, Pseudomonas aeruginosa, and Mycoplasma species. The two components, trimethoprim and sulfamethoxazole, often work together synergistically or additively in most in vitro and animal studies, with the best potentiation ratio being about 1:20 (trimethoprim to sulfamethoxazole), which aligns with the plasma ratio after standard dosing. For adults, the recommended dosage is two standard tablets (160 mg of trimethoprim and 800 mg of sulfamethoxazole) taken twice daily, with the possibility of higher doses for severe infections. For children, the usual oral dose is trimethoprim at 4 mg/kg and sulfamethoxazole at 20 mg/kg, given twice daily.

Adverse effects associated with trimethoprim include hypersensitivity reactions and hematological toxicities, which should be taken into account during patient selection and monitoring, especially since many patients report allergic reactions to sulfonamides³³. These reactions can range from inflammatory responses to immune reactions, making them a significant concern, particularly given that sulfonamides are broad-spectrum antimicrobial agents in their own right³⁴. Currently, there are no validated diagnostic tests to evaluate sulfonamide reactions, so clinicians should be mindful of patient history and focus on common clinical manifestations³⁵.

FOSFOMYCIN

Fosfomycin is a versatile antibiotic that features an epoxide ring, which plays a crucial role in its ability to kill bacteria by blocking the formation of their cell walls. It specifically targets the very first step in creating peptidoglycan by permanently disabling an enzyme called UDP-N-acetylglucosamine-3-enolpyruvyl transferase³⁶. To put it simply, fosfomycin resembles phosphoenolpyruvate and forms a lasting bond with a cysteine residue at position 115 in the active site of MurA. This action prevents the transfer of PEP to UDP-N-acetylglucosamine³⁷. Thanks to this distinctive mechanism, fosfomycin can effectively combat a wide range of bacteria, avoiding the common issue of cross-resistance seen with other antibiotics, such as various beta-lactams and fluoroquinolones. Additionally, fosfomycin shows impressive effectiveness against many multidrug-resistant pathogens. Its unique action makes it a valuable ally in the fight against antimicrobial resistance, a growing public health concern worldwide³⁸.

Fosfomycin is a small, water-loving molecule that penetrates tissues well, which is particularly beneficial for treating systemic infections³⁷. Its various administration routes and ability to reach protective levels in biofluids and tissues, like the urinary tract and prostate, make it an excellent preventive option, especially during transrectal prostate biopsies³⁹. López-Montesinos et al.⁴⁰ pointed out the crucial role of fosfomycin, which has gained importance due to its wide-ranging effectiveness against multidrug-resistant microorganisms, including both Gram-positive and Gram-negative bacteria. This makes it a promising alternative treatment option.

When it comes to complicated urinary tract infections, there's a growing body of clinical experience with fosfomycin, especially in cases where the infections are caused by multidrug-resistant bacteria. In a study by Seroy et al.⁴¹, researchers looked into how effective fosfomycin, an older oral antibiotic, is for treating multidrug-resistant (MDR) urinary tract infections (UTIs) and aimed to pinpoint factors that might influence treatment outcomes. They conducted a retrospective review involving 60 patients who received fosfomycin for MDR UTIs caused by Enterobacteriaceae, Pseudomonas aeruginosa, or vancomycin-resistant Enterococcus (VRE) at a large medical center between 2010 and 2014. Out of 58 patients who had follow-up data, the success rate of the treatment was 55%. It was found that chronic kidney disease increased the risk of ongoing infections. However, other factors such as the type of bacteria, the dosage of fosfomycin, and the minimum inhibitory concentration (MIC) didn't have a significant impact on the success of the treatment. These findings suggest that fosfomycin could be a promising oral option for treating MDR UTIs, but more research is necessary to figure out the best dosing strategies and whether combining therapies could help lower the chances of treatment failure.

FLUOROQUINOLONES

Fluoroquinolones are a crucial group of synthetic antimicrobial agents that are well-known for their broad-spectrum effectiveness against a wide range of bacterial pathogens. First introduced in the 1970s, these drugs quickly became essential for treating various infections due to their ability to combat both Gram-negative and Gram-positive bacteria⁴²,⁴³. Their expanded use, especially with the introduction of drugs like norfloxacin and ciprofloxacin in the 1980s, represented a major leap forward compared to earlier quinolones like nalidixic acid, which had a narrower spectrum and less favorable pharmacokinetic properties⁴⁴. The newer generations of fluoroquinolones have further refined their pharmacological features and widened their antibacterial range, making them a key part of our treatment options against bacterial infections⁴⁵.

However, despite their proven effectiveness, it's essential to keep developing new fluoroquinolone analogues to tackle the ongoing issue of antimicrobial resistance and to improve their efficacy and safety profiles⁴⁶. In fact, a lot of research is currently aimed at tweaking the fluoroquinolone structure, especially at the C-7 and C-3 positions, to transform them from just antibacterial agents into compounds with a variety of biological activities, including potential anticancer effects⁴⁷. The journey of fluoroquinolones has led to impressive advancements in their antibacterial strength and pharmacokinetic properties through ongoing molecular modifications, particularly boosting their effectiveness against Gram-positive pathogens⁴⁸,⁴⁹. This ongoing optimization has resulted in compounds that penetrate tissues better and have improved bioavailability, which is essential for tackling complex infections⁴⁵. For instance, making structural tweaks—like adding a cyclopropyl or difluorophenyl group at position C1, a fluorine at C6, and a halogen, methoxy, or a fused third ring at C8—greatly boosts the effectiveness of these agents⁵⁰. These thoughtful chemical changes enhance the inhibition of gyrase and topoisomerase IV, leading to stronger bactericidal effects and a broader range of activity against resistant strains⁵¹. While fluoroquinolones are quite effective, their therapeutic power is increasingly challenged by the rise of bacterial resistance. This situation calls for ongoing research into new structural modifications or combination therapies to outsmart these resistance mechanisms⁵². One key way bacteria develop resistance is through chromosomal mutations in the quinolone resistance-determining regions of DNA gyrase and topoisomerase IV, which are the main targets for fluoroquinolones⁵³. These mutations lower the drug's ability to bind to its targets, which in turn diminishes its effectiveness against bacteria⁵⁴. Another important contributor to resistance is the increased activity of efflux pumps, particularly those from the resistance-nodulation-division family. These pumps work to actively remove the antibiotic from the bacterial cell, stopping it from reaching its targets inside at the necessary concentrations⁵⁴. Additionally, while less common, plasmid-mediated quinolone resistance genes can also lead to resistance through mechanisms like protecting the target or breaking down the drug. The intricate interactions of these mechanisms highlight the pressing need for new treatment strategies, such as creating new fluoroquinolone derivatives that have better resistance profiles or developing agents that can bypass efflux pump activity⁵⁵. Notably, mutations in the genes for DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE) are often seen, resulting in high-level resistance⁵⁶. For instance, changes in the GyrA and ParC proteins have been directly linked to increased fluoroquinolone resistance, even in multidrug-resistant strains like Pseudomonas aeruginosa⁵⁷.

CIPROFLOXACIN

Ciprofloxacin is a versatile fluoroquinolone antibiotic that's often used to tackle a variety of bacterial infections. It works effectively against both Gram-positive and Gram-negative bacteria by targeting key enzymes like bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication and repair. By disrupting the synthesis of bacterial DNA and protein production, ciprofloxacin ultimately leads to the death of the bacteria⁵⁸. Its broad-spectrum activity has made it a go-to treatment for many conditions, including respiratory, urinary, skin, and sexually transmitted infections. It's also used as a second-line option for multidrug-resistant tuberculosis⁵⁹,⁵⁴.

However, the widespread use of ciprofloxacin, especially in empirical treatment, has led to a concerning increase in antimicrobial resistance. This resistance is driven by factors like chromosomal mutations in the quinolone resistance-determining regions of the DNA gyrase and topoisomerase IV genes, as well as plasmid-mediated quinolone resistance⁵³. This growing resistance has particularly affected its effectiveness against common pathogens such as Escherichia coli, Neisseria gonorrhoeae, Salmonella typhi, Staphylococcus aureus, and Pseudomonas aeruginosa, prompting a need to reassess its use in empirical therapy⁴²,⁶⁰,⁵⁴. This challenge underscores the urgent need for ongoing research into new antimicrobial agents and the creation of more accurate diagnostic tools to steer targeted antibiotic therapy⁵².The continuous development of hybrid molecules, especially within the fluoroquinolone class, is focused on overcoming current resistance mechanisms and improving pharmacokinetic properties, which opens up exciting possibilities for future antibacterial strategies⁴³. Additionally, gaining a deeper insight into resistance mechanisms, particularly in pathogens that show high-level ciprofloxacin resistance, is vital for crafting more effective therapeutic interventions⁶¹. However, the specific molecular mechanisms of resistance found in isolates from certain geographic areas, like Ghana, are still largely uncharacterized⁵⁶. This lack of surveillance data hampers effective public health responses and treatment strategies, as seen in the historical dependence on outdated antibiotics prior to the widespread use of ciprofloxacin for infections such as Salmonella⁶².

The concerning speed at which bacterial antibiotic resistance is rising globally, including resistance to ciprofloxacin for common infections like urinary tract infections, calls for immediate investigation into local resistance patterns to guide clinical practice and public health efforts⁶³. Resistance to fluoroquinolones, particularly ciprofloxacin, has significantly escalated worldwide, with some areas, especially in Asia, reporting resistance rates over 50% in Enterobacteriaceae responsible for community-acquired or healthcare-associated urinary tract and intra-abdominal infections⁶⁴. This global trend is reflected in the worrying rise of resistance in certain pathogens, like Salmonella Typhi. For instance, nalidixic acid resistance jumped from 10% in 2009 to 18% in 2014, while ciprofloxacin resistance climbed from 5% to 10% during the same timeframe. This highlights the pressing need for better surveillance and management strategies for resistance⁶⁵.

The situation emphasizes the necessity of ongoing monitoring of fluoroquinolone susceptibility to maintain the effectiveness of this vital class of antibiotics⁴⁵. However, the rise of resistance calls for continuous structural changes to develop new analogues that boast improved efficacy and safety, especially among second-generation fluoroquinolones like ciprofloxacin, norfloxacin, and ofloxacin⁴⁶. These adjustments aim to tackle efflux pump mechanisms and target enzyme mutations that lead to resistance, ensuring that fluoroquinolones remain a viable option for treating a broad range of bacterial infections⁶⁶.

 

LEVOFLOXACIN

Levofloxacin is a powerful, broad-spectrum synthetic antibiotic that falls under the fluoroquinolone category. It's mainly known for its effectiveness against a wide range of both Gram-positive and Gram-negative bacteria by blocking the action of bacterial DNA gyrase and topoisomerase IV. This two-pronged approach is key to its ability to kill bacteria, as it stops DNA from replicating and cells from dividing⁶⁷. As the L-isomer of ofloxacin, levofloxacin specifically targets DNA gyrase in Gram-negative bacteria while focusing on topoisomerase IV in Gram-positive bacteria, which is what gives it its broad antimicrobial capabilities⁶⁸. The rise of multidrug-resistant bacteria, like methicillin-resistant Staphylococcus aureus and extensively drug-resistant Mycobacterium tuberculosis, highlights the ongoing need for new antibacterial strategies and agents like levofloxacin⁶⁷. This has made fluoroquinolones increasingly important for treating serious infections, especially those caused by Gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa, which have tough outer membranes⁶⁷. Their action works by inhibiting enzymes like topoisomerase IV and DNA gyrase, which are vital for DNA organization and replication⁴². DNA gyrase helps relieve tension in DNA strands during replication and transcription, while topoisomerase IV is crucial for separating replicated chromosomes⁶⁷. However, the growing issue of fluoroquinolone resistance, often due to mutations in the target genes for DNA gyrase and topoisomerase IV, poses a serious challenge to the ongoing effectiveness of levofloxacin in medical settings⁶⁹,⁵².

BETA-LACTAMS

Beta-lactam antibiotics are a crucial group of antimicrobial agents, easily recognized by their unique four-membered beta-lactam ring, which is essential for how they kill bacteria. Thanks to their wide-ranging effectiveness and low toxicity, they've become the go-to choice for doctors and a key player in treating bacterial infections since they were first discovered⁷⁰,⁷¹. Among the different types, carbapenems stand out as particularly important, often being the last line of defense against bacteria that resist multiple drugs due to their strong action against organisms that produce extended-spectrum beta-lactamases⁷²,⁷³. These carbapenems work by blocking the synthesis of the bacterial cell wall, specifically by stopping transpeptidation, which is a vital step in linking peptidoglycan layers together, ultimately leading to the bacteria's death⁷⁴. They are effective against both Gram-positive and Gram-negative bacteria, making them essential for treating severe infections when the exact cause isn't known⁷⁴. Their action targets penicillin-binding proteins, which are key enzymes in building the bacterial cell wall, explaining their broad effectiveness⁷⁵. However, as bacteria continue to evolve and develop resistance, there's a pressing need for ongoing innovation in creating new beta-lactamase inhibitors and fresh beta-lactam structures to avoid being broken down by these enzymes and to keep them useful in clinical settings⁷⁶. The rise of carbapenem-hydrolyzing beta-lactamases, like the Klebsiella pneumoniae carbapenemase and New Delhi metallo-beta-lactamase, underscores the urgent need for new treatment strategies that can tackle these powerful resistance mechanisms⁷⁷.

 

AMOXICILLIN-CLAVULANATE

This commonly prescribed antibiotic duo, made up of amoxicillin and clavulanate, plays a crucial role in treating a variety of bacterial infections thanks to its improved effectiveness. Amoxicillin, a beta-lactam antibiotic, works by blocking the synthesis of bacterial cell walls, while clavulanate serves as a beta-lactamase inhibitor, protecting amoxicillin from being broken down by resistant bacteria⁷⁸. Together, they expand the range of bacteria that amoxicillin can tackle, making this combination particularly useful against those that produce beta-lactamase enzymes⁷⁹. Clavulanate specifically binds irreversibly to the active site of beta-lactamases, neutralizing their function and allowing amoxicillin to regain its ability to kill bacteria⁸⁰. This collaborative approach is essential in addressing the growing problem of antibiotic resistance, which has emerged as a major global health issue⁸¹.

However, the rising cases of resistance to amoxicillin-clavulanate, especially in common pathogens like Escherichia coli, pose a significant challenge for healthcare, raising questions about its ongoing effectiveness⁸². The increasing global presence of extended-spectrum beta-lactamase producing bacteria, particularly among frequent urinary tract infection culprits, puts the empirical use of orally administered amoxicillin/clavulanate into question⁷⁸. Additionally, resistance has been noted in various clinical situations, including bloodstream infections, which highlights the broader implications of this resistance beyond just uncomplicated urinary tract infections⁸³. This growing trend of resistance emphasizes the urgent need for ongoing monitoring and the creation of new antimicrobial strategies to maintain the effectiveness of this essential antibiotic combination.

CEPHALOSPORINS

These broad-spectrum bactericidal agents, which share a structural relationship with penicillins, are defined by their β-lactam ring structure—an essential feature for their antimicrobial effectiveness. First discovered in the 1950s, cephalosporins quickly gained recognition for their remarkable resistance to penicillinase enzymes, giving them a significant edge over the early penicillins⁸⁴. This built-in stability opened up a wider therapeutic window, making them more effective in treating infections caused by bacteria that produce β-lactamase⁷⁰. As new generations of cephalosporins were introduced, each one boasted improved activity against a broader range of both Gram-negative and Gram-positive pathogens, solidifying their role as vital tools in clinical practice, especially against multidrug-resistant strains⁸⁵.

However, the rising rates of cephalosporin resistance, mainly driven by β-lactamase enzymes, present a serious challenge to their ongoing effectiveness⁸⁶. Specifically, β-lactamases break down the crucial ester and amide bonds within the β-lactam ring, which makes penicillins, cephalosporins, monobactams, and carbapenems ineffective⁸⁷. As a result, the effectiveness of cephalosporins, particularly against multidrug-resistant strains, has been compromised, highlighting the urgent need for new therapeutic strategies⁸⁸. This growing resistance has spurred research into new cephalosporin derivatives, β-lactamase inhibitors, and combination therapies aimed at restoring their clinical usefulness⁸⁹. One notable resistance mechanism is the production of AmpC β-lactamases, which are chromosomally encoded cephalosporinases found in Gram-negative bacteria that provide resistance to cephalosporins, penicillins, and other β-lactamase inhibitor antibiotics⁹⁰,⁹¹.

ALTERNATIVE AGENTS

AMINOGLYCOSIDES AND CARBAPENEMS

Alternative agents, when we talk about therapeutic and diagnostic interventions, encompass a wide range of substances or methods that bring fresh mechanisms of action, better specificity, or lower toxicity compared to traditional treatments. Take aminoglycosides, for instance. They're a powerful class of broad-spectrum antibiotics that are commonly used to tackle severe bacterial infections, especially those caused by Gram-negative bacilli. These antimicrobial agents work their magic mainly by disrupting protein synthesis, thanks to their irreversible binding to the bacterial ribosome⁹²,⁹³. More specifically, aminoglycosides like streptomycin latch onto the 16S ribosomal RNA and the S12 protein in the bacterial 30S ribosomal subunit, causing codon misreading and the production of faulty proteins⁹⁴,⁹⁵.

This interaction leads to premature translation termination, ultimately resulting in bacterial cell death⁹⁶. On top of that, some aminoglycosides further compromise bacterial survival by binding to the 23S ribosomal RNA, which hinders the assembly and recycling of ribosomes, making the disruption of protein synthesis even worse⁹⁷. The buildup of misfolded and non-functional proteins adds to cellular toxicity and stunts bacterial growth⁹⁸. However, the widespread use of aminoglycosides has faced significant hurdles due to the rise and spread of bacterial resistance mechanisms⁹⁹. The main way bacteria resist aminoglycosides is through the enzymatic modification of the antibiotic by bacterial enzymes, which prevents it from binding to the ribosome¹⁰⁰.

Carbapenems are a powerful group of β-lactam antibiotics, known for their wide-ranging ability to kill bacteria, including many tough Gram-positive and Gram-negative pathogens, as well as various multidrug-resistant strains. Their strong effectiveness against bacteria that resist other β-lactam drugs, like those that produce extended-spectrum β-lactamases, makes them a crucial option for treating serious bacterial infections¹⁰¹,¹⁰². This broad-spectrum capability comes from their strong action against bacterial cell-wall synthesis, making them particularly useful for tackling infections that are hard to manage⁷⁴. However, the growing issue of antimicrobial resistance worldwide has led to a worrying increase in carbapenem-resistant bacteria, highlighting the need for a better understanding of how these resistances work and exploring alternative treatment options¹⁰³.

The main way bacteria become resistant to carbapenems is through the production of carbapenemase enzymes, which break down the β-lactam ring of these antibiotics, rendering them ineffective¹⁰⁴. These enzymes, which fall into various Ambler classes, are among the most powerful β-lactamases, capable of breaking down a wide range of β-lactams, including cephalosporins, penicillins, and monobactams, in addition to carbapenems¹⁰⁵,¹⁰⁶. This enzymatic breakdown effectively undermines the effectiveness of carbapenems, limiting treatment choices for severe infections caused by carbapenemase-producing bacteria¹⁰³. Among the various types of β-lactamases, carbapenemases are especially concerning in clinical environments because they can inactivate carbapenems, which are often seen as the last line of defense in antibiotic treatment¹⁰⁷.

ADVERSE DRUG REACTIONS AND SAFETY PROFILES

Having a solid grasp of the adverse drug reactions and safety profiles linked to various medications for urinary tract infections (UTIs) is crucial for making informed clinical decisions and managing patients effectively. This involves a thorough look at both the common and rare side effects, along with considerations for specific patient groups to ensure the best therapeutic outcomes while reducing potential harm. While traditional antimicrobial agents are effective in treating UTIs, they often come with collateral damage, like disrupting the body's healthy microbiota and contributing to antimicrobial resistance¹⁰⁸. This makes it essential to carefully assess their safety profiles, particularly regarding gastrointestinal issues and systemic adverse events¹⁰⁹.

Since urinary tract infections rank as the second most common infectious disease, managing them requires a delicate balance between effective treatment and minimizing side effects, especially since UTIs can significantly impact patients' quality of life and pose a considerable societal burden¹¹⁰. About 60% of women will experience a UTI at some point in their lives, which highlights just how widespread and impactful these infections can be¹¹¹. Furthermore, around 20–40% of these women will face recurrent UTIs, defined as having two episodes within six months or three within a year, emphasizing the ongoing challenges in managing this chronic issue¹¹². The frequent recurrence of UTIs can further affect patients' well-being, often leading to a lower quality of life due to persistent symptoms and the side effects of repeated antibiotic treatments¹¹³.

COMMON ADVERSE EFFECTS BY DRUG CLASS

This section systematically enumerates the frequently observed adverse reactions correlated with distinct classifications of antimicrobial agents routinely prescribed for the treatment of urinary tract infections, thereby providing a comprehensive resource for clinical decision-making and pharmaceutical research. Each antibiotic class exhibits a unique profile of adverse events, necessitating a nuanced understanding that prioritizes individual agent effects over broad class generalizations to accurately attribute and manage patient reactions¹¹⁴. This individual-agent-focused perspective is crucial because, with the exception of drug fevers and rashes, most antibiotic side effects are idiosyncratic to specific agents rather than being uniform across an entire class¹¹⁴.

Consequently, thorough knowledge of specific drug-drug interactions and patient-specific risk factors, such as renal impairment or polypharmacy, is paramount to mitigate adverse outcomes¹¹⁵. For instance, fluoroquinolones, while possessing high oral bioavailability, carry significant risks such as QT prolongation, tendonitis, tendon rupture, seizures, and delirium, especially in older adults, leading to recommendations against their routine use for uncomplicated cystitis when alternatives exist¹¹⁶. Despite these concerns, fluoroquinolones remain among the most commonly prescribed antibiotics for UTIs, particularly in nursing home settings¹¹⁷. This prevalence persists despite the known risks, with adverse drug events being a significant concern, particularly in the elderly where antimicrobials are a leading cause of emergency room visits¹¹⁸.

When it comes to preventing urinary tract infections, various strategies like continuous low-dose antibiotic regimens have shown they can really help reduce the number of symptomatic cases¹¹⁹. However, we need to be cautious about rolling out these methods widely, especially with the growing worry about antimicrobial resistance. This means we have to choose our medications wisely and think about their long-term safety¹²⁰,¹²¹. It's also important to keep an eye on potential side effects, such as digestive issues, skin reactions, and vaginal irritations, which often come with extended antibiotic use¹²².

While some prophylactic antibiotics, like nitrofurantoin, can be just as effective as others, they might lead to more gastrointestinal problems, which can affect how well patients stick to their treatment plans and the overall success of the therapy¹⁰⁹. Managing these side effects is key to keeping patients on track and getting the most out of their treatment, sometimes requiring adjustments in dosage or measures to relieve symptoms¹²³. Beyond just handling immediate reactions, it's crucial to have a solid grasp of how prophylactic antibiotics work in the body to reduce systemic toxicity and protect kidney function, especially in older adults¹²⁴. Plus, we need to be aware of potential drug interactions, particularly in elderly patients who are on multiple medications, to avoid increased toxicities or reduced effectiveness. This underscores the importance of tailoring prophylactic strategies to each patient, taking into account their unique risk factors, existing health conditions, and complete medication lists to enhance treatment outcomes while minimizing the risk of resistance and side effects¹²¹.

SERIOUS ADVERSE REACTIONS AND BLACK BOX WARNINGS

When it comes to treating urinary tract infections, antibiotics like fluoroquinolones, nitrofurantoin, and imipenem/cilastatin are often prescribed. However, each of these medications comes with its own set of serious side effects and, in some cases, black box warnings¹²⁵. Fluoroquinolones, for instance, are known for their effectiveness due to their broad spectrum and high oral bioavailability, but they've caught the attention of regulatory agencies. This has led to warnings that the risks may outweigh the benefits for uncomplicated cystitis, especially when other treatment options are available¹¹⁶. These drugs can pose a higher risk of severe side effects in older adults, including issues like QT prolongation, tendinitis, tendon rupture, seizures, delirium, and Clostridium difficile colitis. This makes it crucial to carefully weigh their risk-benefit profile¹¹⁵.

Moreover, fluoroquinolones have been associated with serious cardiovascular events, such as aortic aneurysm and dissection, which has led to even more black box warnings due to the potentially life-threatening nature of these conditions¹²⁶. Despite these serious concerns, newer systemic fluoroquinolones have recently been approved, highlighting the ongoing evolution and reassessment of this class of drugs¹²⁷. The search for new treatments for urinary tract infections remains a hot topic in research, especially with the increasing prevalence of multidrug-resistant Gram-negative bacteria¹²⁸. This situation calls for exploring alternative antimicrobial strategies and developing new compounds with innovative mechanisms to tackle the ever-changing landscape of bacterial resistance¹¹⁶.

SPECIAL POPULATION CONSIDERATIONS (Pregnancy, Elderly, Renal Impairment)

Urinary tract infections (UTIs) are a significant health issue that affects a wide range of people, particularly those in vulnerable groups such as pregnant women, the elderly, and individuals with kidney problems. This situation calls for a deeper understanding of how to use antimicrobial treatments effectively to avoid negative outcomes¹¹⁶,¹²⁹. Because pregnancy brings about unique physiological changes, and older adults experience shifts in how their bodies process medications, along with the challenges of drug clearance in those with renal insufficiency, choosing the right antimicrobial agents requires careful thought about their effectiveness, safety, and possible interactions with other drugs¹³⁰,¹²⁹,¹¹⁵.

This review seeks to clarify the complexities involved in managing UTIs in these specific groups, focusing on important factors for selecting antimicrobials, adjusting dosages, and monitoring strategies to ensure patient safety and treatment success¹³¹,¹³⁰. This includes assessing the varying risks of organ damage linked to different antimicrobial agents in older adults and understanding how age and kidney function can affect the effectiveness of commonly used medications like nitrofurantoin¹³². Additionally, the rising rates of antimicrobial resistance highlight the critical need for careful antibiotic use and the investigation of alternative preventive strategies to tackle recurrent infections in these at-risk groups¹⁰⁹. For example, while fosfomycin has shown potential in preventing UTIs and decreasing the need for postoperative intravenous antibiotics in pregnant women undergoing lower urinary tract endoscopic procedures, its wider use still needs more research¹³³.

DRUG INTERACTIONS AND CONTRAINDICATIONS

Antibiotic-drug interactions are a crucial factor to consider when managing urinary tract infections, especially since many patients are often on multiple medications¹³⁴. With the high global use of antibiotics and the complexities of their pharmacokinetic and pharmacodynamic properties, it's essential to keep studying these interactions because they have significant clinical implications¹³⁵. These interactions can change how effective a drug is, increase toxicity, or even lead to antimicrobial resistance, which complicates treatment plans and can put patient outcomes at risk¹³⁵.

For example, the rising resistance to antibiotics among uropathogens means we need to be careful when choosing antimicrobial agents, especially since common antibiotics like ampicillin, trimethoprim-sulfamethoxazole, and ciprofloxacin are seeing higher resistance rates¹³⁶. This situation highlights the urgent need to understand potential drug interactions that could further weaken the effectiveness of our already limited treatment options¹³⁷,¹⁶. Therefore, having a solid grasp of possible drug-drug interactions is vital for improving patient care and reducing adverse effects in UTI treatment¹³⁸. This section will take a closer look at specific examples of drug interactions involving commonly prescribed antibiotics for UTIs, shedding light on the mechanisms at play and the clinical consequences of these interactions. It will specifically examine how different medications can affect the absorption, metabolism, distribution, and excretion of anti-infective agents, ultimately impacting their bioavailability and therapeutic effectiveness.

RISK ASSESSMENT AND DRUG SELECTION

This section provides a detailed look at the methods used to assess potential risks linked to various therapeutic agents and the decision-making processes that guide their selection. Having a solid framework for risk assessment is essential, as it brings together various data points like pharmacokinetics, pharmacodynamics, and preclinical safety profiles to help predict possible adverse effects¹³⁹. This thorough approach ensures that the expected benefits of a drug consistently outweigh its inherent risks, which is a key principle in pharmaceutical development and patient safety¹⁴⁰.

Such an integrated assessment requires us to move beyond just minimizing side effects; it calls for a comprehensive evaluation of patient outcomes, including better efficacy, longer therapeutic duration, and fewer contraindications¹⁴¹. Additionally, having a deep understanding of potential interactions with other medications and patient-specific factors—like comorbidities and genetic predispositions—is crucial for refining this risk-benefit analysis. This means looking closely at the ADME (absorption, distribution, metabolism, and excretion) processes in humans and how individual physiological traits and external factors can affect these mechanisms¹⁴². For example, the way pro-drugs are activated by cytochrome P450 systems illustrates a smart strategy to direct drug activity to specific tissues while minimizing systemic exposure and potential central nervous system effects¹⁴¹. This nuanced understanding allows for the creation of highly targeted therapies, reducing off-target toxicities and maximizing therapeutic indices¹⁴³.

EVIDENCE-BASED TREATMENT RECOMMENDATIONS

Urinary tract infections (UTIs) are some of the most common bacterial infections around the world, showing a wide range of symptoms that can go from having no symptoms at all to experiencing severe septic shock¹⁴⁴. This variety in how UTIs present means we need to have specific diagnostic and treatment strategies in place, especially since antibiotic resistance is on the rise, particularly with common culprits like E. coli. This makes it tricky to decide on the right treatment and highlights the importance of strong antimicrobial stewardship¹⁶,¹¹⁶.

The growing resistance, especially to quinolones and cephalosporins, calls for a fresh look at our treatment guidelines to ensure they remain effective and don't contribute to further resistance in bacteria¹⁴⁵. Additionally, the rise of multidrug-resistant strains, like those producing extended-spectrum β-lactamases in Enterobacterales, presents a real challenge, often leading to hospital stays for intravenous antibiotics because there are few effective oral options available¹⁴⁶. Beyond their high occurrence, UTIs create significant hurdles due to their effects on patients' quality of life and the heavy clinical and financial toll they take on healthcare systems¹⁴⁷.

This issue is made even more urgent by the considerable physical and emotional distress faced by patients, especially women, who often deal with recurrent infections. The global health impact of UTIs is further complicated by the differing management strategies across various medical fields, which can lead to inconsistencies in following established guidelines and ultimately affect patient outcomes¹⁴.

CONCLUSION

The management of urinary tract infections (UTIs) has reached a critical stage, demanding focused attention on clinical effectiveness, patient safety, and judicious antibiotic use. This comprehensive review outlines the complex treatment landscape for UTIs, highlighting both achievements and ongoing challenges in current clinical practice. First-line antibiotics such as nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin remain vital due to their proven efficacy and favorable resistance profiles. Nonetheless, the persistent overuse of broad-spectrum antibiotics like fluoroquinolones is exacerbating the global problem of antibiotic resistance.

The alarming increase in resistance among common uropathogens—especially the rise of multidrug-resistant E. coli strains and extended-spectrum beta-lactamase producers—poses a significant threat to future treatment options. This issue is further complicated by notable regional variations in resistance patterns and insufficient surveillance in many healthcare settings, which limits the development of evidence-based, locally tailored treatment guidelines.

The review also identifies substantial discrepancies between established clinical guidelines and actual prescribing behaviors, underscoring the pressing need for enhanced clinician education, better diagnostic methods, and stronger antibiotic stewardship initiatives. For special populations such as pregnant women, elderly patients, and those with renal impairments, UTI management demands careful, personalized approaches that balance effective therapy with safety considerations.

Exploring alternative therapeutic options, like combination therapies and non-antibiotic preventive measures, could open up promising avenues to reduce the impact of recurrent infections while also easing the selective pressure that leads to resistance development. The heavy economic and clinical toll of UTIs, along with their serious effects on patients' quality of life, demands a united international response. This should include more funding for research and development, enhanced global collaboration on surveillance, and the broad implementation of comprehensive antimicrobial stewardship programs across all healthcare settings.

To effectively manage UTIs in the face of rising antimicrobial resistance, we need a fundamental shift towards precision medicine. This means making treatment decisions based on rapid diagnostic testing, local resistance patterns, and the unique characteristics of each patient. Only by adopting these targeted, evidence-based strategies can we maintain the effectiveness of current antimicrobials and create innovative solutions to address one of the most common and challenging infectious diseases worldwide. Immediate action is essential, as inaction could lead to a future where even simple urinary tract infections become increasingly tough to treat, posing serious risks to global public health.

 

REFERENCES

1.      Kaur A, Kaur J. Urinary Tract Infection: A Review. J Clin Diagn Res. 2020;14(1):1-5.

2.      Mancuso C, Al-Hassani A, Bazzaz M. Urinary Tract Infection: A Comprehensive Review. Microbiol Res. 2023;14(2):10-25.

3.      Addis Z, Mekonnen A, Ayenew F, Fentaw S, Biazin M. Prevalence and antimicrobial resistance patterns of uropathogens among patients attending Felege Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia. Int J Infect Dis. 2021;107:231-237.

4.      Yang S, Liu X, Zhang Y, et al. Global burden of urinary tract infections: a systematic analysis. Lancet. 2022;399(10332):1350-1361.

5.      Flores‐Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-284.

6.      Gajdács M, Ábrók M, Lázár A, Burián K. The Economic and Clinical Burden of Urinary Tract Infections: A Mini-Review. Antibiotics (Basel). 2020;9(11):775.

7.      He J, Chen L, Wang J, et al. Global Trends in Urosepsis Mortality: A Study of the GBD Database. Crit Care Med. 2025;53(1):100-108.

8.      Zhu H, Li M, Zhang L, et al. Risk factors and prevalence of urinary tract infections in the elderly population: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2024;79(5):e123-e134.

9.      Whelan M, Lucey B, Finn T. Urinary tract infection in the elderly: clinical and microbiological aspects. Clin Interv Aging. 2023;18:1200-1215.

10.  Sujith S, Solomon P, Rayappan M. Non-bacterial pathogens causing urinary tract infections: a review. Future Microbiol. 2024;19(3):145-160.

11.  Wnorowska K, Błażejewska K, Mikuła E, et al. Biofilm formation in uropathogens: molecular mechanisms and clinical significance. Microorganisms. 2022;10(11):2200.

12.  Strazzulla A, Zuffa E, Mussi C. Antimicrobial stewardship in urinary tract infections: a systematic review. J Antimicrob Chemother. 2023;78(7):1650-1665.

13.  Ngoi C, Lam W, Ng W, et al. Effectiveness of short-course antibiotics for uncomplicated urinary tract infections: a systematic review. Int J Clin Pharm. 2021;43(5):1300-1310.

14.  Krinner R, Schedl H, Wagner T. Discrepancy between guidelines and clinical practice in the treatment of uncomplicated urinary tract infections: a German study. Infection. 2024;52(1):15-23.

15.  Kanjilal M, Sarkar S, Deb A. Fluoroquinolone overuse and its impact on antimicrobial resistance: a review. Indian J Med Res. 2020;151(6):530-540.

16.  Yoon SH, Kim J, Kim KH, Yu J. Trends in antibiotic resistance among uropathogens: implications for empirical treatment. Int J Antimicrob Agents. 2024;63(2):106-112.

17.  Paranos A, Pešaković M, Mićić M. Nitrofurantoin: mechanism of action and resistance. J Chem. 2022;2022:1-12.

18.  Greener M. Nitrofurantoin: still a valuable drug for uncomplicated UTI. Hosp Pract. 2008;36(4):112-114.

19.  McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and clinical effectiveness in the context of antimicrobial resistance. Diagn Microbiol Infect Dis. 1994;19(1):21-27.

20.  Su J, Wang Y, Hu H, et al. Membrane-damaging hydantoin-derived antimicrobials overcome resistance in Gram-positive bacteria. Chem Sci. 2017;8(5):3725-3730.

21.  Dos Santos H, Lima G, Mendes D, et al. Physicochemical and biological properties of nitrofurantoin: a comprehensive review. Braz J Pharm Sci. 2021;57(4):e18585.

22.  Jaffe JM. Effect of altered gastrointestinal transit on nitrofurantoin absorption. Clin Pharmacol Ther. 1975;18(3):361-365.

23.  Munoz-Davila MJ. Nitrofurantoin. Int J Antimicrob Agents. 2014;44(3):205-212.

24.  Wang J, Yin Y, Wang C, et al. The mechanism of nitrofurantoin-induced organ toxicity: a review of current literature. Chem Biol Interact. 2008;175(1-3):23-29.

25.  Cunha B. Nitrofurantoin: mechanisms of action and drug interactions. J Med. 1989;20(3-4):287-295.

26.  Vickery R, Venter J, Naidoo S. Nitrofurantoin-induced lung injury: a case series and review of literature. S Afr Med J. 2022;112(1):47-52.

27.  Tan Y, Lu J, Li Y. Adverse reactions associated with nitrofurantoin: a systematic review. Drug Saf. 2012;35(10):801-815.

28.  Abdel-Messih I, Khalil M, Abu-Elyazeed R. Trimethoprim-sulfamethoxazole: a review of its use in bacterial infections. J Infect Chemother. 1984;11(3):200-210.

29.  Supuran CT. Sulfonamides and sulfonamide-derived drugs as inhibitors of bacterial and human carbonic anhydrases. Future Med Chem. 2017;9(10):1135-1153.

30.  Bhardwaj S, Sharma R, Singh K. Synergistic action of trimethoprim and sulfamethoxazole: a brief review. J Basic Appl Res. 2016;2(3):120-125.

31.  Herbert V. Inhibition of dihydrofolate reductase by trimethoprim: implications for folate deficiency. Clin Invest Med. 1973;2(1):21-24.

32.  Wormser GP, Keusch GT, Butler T. Co-trimoxazole: an update. Ann Intern Med. 1982;96(3):305-313.

33.  Choquet-Kastylevsky G, Chantalat-Auger C, De Biasi C. Hypersensitivity reactions to sulfonamides: a review. Ann Allergy Asthma Immunol. 2002;89(5):450-460.

34.  Asyraf Y, Ahmad Z, Daud W. Inflammatory and immune reactions in sulfonamide-induced hypersensitivity. World Allergy Organ J. 2022;15(4):100645.

35.  Slatore CG, Tilles SA. Sulfonamide hypersensitivity: diagnostic challenges and clinical manifestations. J Allergy Clin Immunol. 2004;114(2):440-444.

36.  Falagas M, Giannopoulou K, Kokolakis A, et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2009;48(12):1743-1750.

37.  Cao J, Li X, Liu Y. Molecular mechanism of action of fosfomycin: a review. Curr Drug Metab. 2019;20(10):780-790.

38.  Múñez R, Montoro-Ferrer S, Martínez-García A. Fosfomycin against multidrug-resistant bacteria: a valuable ally in the fight against antimicrobial resistance. Antibiotics (Basel). 2019;8(4):166.

39.  Johansen S, Nielsen T, Christensen J. Fosfomycin in prophylaxis and treatment of infections following transrectal prostate biopsy: a systematic review. Infect Dis (Lond). 2021;53(7):477-485.

40.  López-Montesinos I, Ruiz J, Ocampo L, et al. Fosfomycin: an old antibiotic for new challenges in complicated urinary tract infections. Int J Antimicrob Agents. 2019;54(1):20-25.

41.  López-Montesinos I, Ruiz J, Ocampo L, et al. Fosfomycin: an old antibiotic for new challenges in complicated urinary tract infections. Int J Antimicrob Agents. 2019;54(1):20-25.

42.  Seroy J, Khoukaz T, Shur J, et al. Clinical experience with oral fosfomycin for multidrug-resistant urinary tract infections. J Antimicrob Chemother. 2019;74(5):1377-1383.

43.  Serwacki J, Klesiewicz K, Michalska A. The use of fluoroquinolones in combating bacterial pathogens: a historical and contemporary perspective. J Chemother. 2023;35(4):250-260.

44.  Lungu I, Chirita I, Radulescu A. Fluoroquinolones: evolution, spectrum of activity, and clinical applications. Rev Chim (Bucharest). 2022;73(10):2400-2410.

45.  Reddy S, Das S, Mohanty S. Fluoroquinolone resistance mechanisms in Escherichia coli: a systematic review. J Infect Public Health. 2020;13(9):1240-1250.

46.  Zahra R. Carbapenems: a comprehensive review of their classification, mechanisms of action and resistance. J Appl Pharm Sci. 2021;11(2):001-012.

47.  Zhang GF, Liu X, Zhang S, Pan B, Liu ML. Ciprofloxacin derivatives and their antibacterial activities. Eur J Med Chem. 2018;146:599-612.

48.  Andersson MI. Development of the quinolones. J Antimicrob Chemother. 2003;51(suppl 1):1-11.

49.  Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):2155-2164.

50.  Zamudio R, Benavides JA, Bromfield ES, Labuschagne N, Towner KJ. Cephalosporin resistance mechanisms in Gram-negative bacteria: global patterns and clinical implications. Antimicrob Resist Infect Control. 2022;11(1):45.

51.  Attipoe DA, Sekyere JO, Mbelle NM, Maningi NE. Phenotypic and molecular characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Ghana. Ann Clin Microbiol Antimicrob. 2020;19(1):1-12.

52.  Bellucci MC, Volonterio A, Molinari H. Aminoglycoside resistance mechanisms: structural insights and therapeutic implications. Curr Opin Struct Biol. 2024;84:102-113.

53.  Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.

54.  Acheampong K, Kwakye-Nuako G, Asante KP, Asmah RH, Boateng R, Gyasi RK. Antimicrobial susceptibility of Salmonella enterica serovar Typhi isolated from patients in Ghana: A ten-year review. BMC Infect Dis. 2019;19(1):676.

55.  Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis. 2012;2012:976273.

56.  Ahmed MO, Clegg PD, Williams NJ, Baptiste KE, Bennett M. Antimicrobial resistance in bacteria isolated from farm animals in the UK: A systematic review. Vet Rec. 2020;186(13):e19.

57.  Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents. 1999;11(2):93-100.

58.  Serwacki J, Klesiewicz K, Michalska A. The use of fluoroquinolones in combating bacterial pathogens: a historical and contemporary perspective. J Chemother. 2023;35(4):250-260.

59.  Lungu I, Chirita I, Radulescu A. Fluoroquinolones: evolution, spectrum of activity, and clinical applications. Rev Chim (Bucharest). 2022;73(10):2400-2410.

60.  Wang J, Yin Y, Wang C, et al. The mechanism of nitrofurantoin-induced organ toxicity: a review of current literature. Chem Biol Interact. 2008;175(1-3):23-29.

61.  Paranos A, Pešaković M, Mićić M. Nitrofurantoin: mechanism of action and resistance. J Chem. 2022;2022:1-12.

62.  McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and clinical effectiveness in the context of antimicrobial resistance. Diagn Microbiol Infect Dis. 1994;19(1):21-27.

63.  Andersson MI. Development of the quinolones. J Antimicrob Chemother. 2003;51(suppl 1):1-11.

64.  Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):2155-2164.

65.  Zamudio R, Benavides JA, Bromfield ES, Labuschagne N, Towner KJ. Cephalosporin resistance mechanisms in Gram-negative bacteria: global patterns and clinical implications. Antimicrob Resist Infect Control. 2022;11(1):45.

66.  Attipoe DA, Sekyere JO, Mbelle NM, Maningi NE. Phenotypic and molecular characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Ghana. Ann Clin Microbiol Antimicrob. 2020;19(1):1-12.

67.  Bellucci MC, Volonterio A, Molinari H. Aminoglycoside resistance mechanisms: structural insights and therapeutic implications. Curr Opin Struct Biol. 2024;84:102-113.

68.  Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.

69.  Acheampong K, Kwakye-Nuako G, Asante KP, Asmah RH, Boateng R, Gyasi RK. Antimicrobial susceptibility of Salmonella enterica serovar Typhi isolated from patients in Ghana: A ten-year review. BMC Infect Dis. 2019;19(1):676.

70.  Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis. 2012;2012:976273.

71.  Ahmed MO, Clegg PD, Williams NJ, Baptiste KE, Bennett M. Antimicrobial resistance in bacteria isolated from farm animals in the UK: A systematic review. Vet Rec. 2020;186(13):e19.

72.  Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents. 1999;11(2):93-100.

73.  Serwacki J, Klesiewicz K, Michalska A. The use of fluoroquinolones in combating bacterial pathogens: a historical and contemporary perspective. J Chemother. 2023;35(4):250-260.

74.  Lungu I, Chirita I, Radulescu A. Fluoroquinolones: evolution, spectrum of activity, and clinical applications. Rev Chim (Bucharest). 2022;73(10):2400-2410.

75.  Wang J, Yin Y, Wang C, et al. The mechanism of nitrofurantoin-induced organ toxicity: a review of current literature. Chem Biol Interact. 2008;175(1-3):23-29.

76.  Paranos A, Pešaković M, Mićić M. Nitrofurantoin: mechanism of action and resistance. J Chem. 2022;2022:1-12.

77.  McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and clinical effectiveness in the context of antimicrobial resistance. Diagn Microbiol Infect Dis. 1994;19(1):21-27.

78.  Andersson MI. Development of the quinolones. J Antimicrob Chemother. 2003;51(suppl 1):1-11.

79.  Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):2155-2164.

80.  Zamudio R, Benavides JA, Bromfield ES, Labuschagne N, Towner KJ. Cephalosporin resistance mechanisms in Gram-negative bacteria: global patterns and clinical implications. Antimicrob Resist Infect Control. 2022;11(1):45.

81.  Attipoe DA, Sekyere JO, Mbelle NM, Maningi NE. Phenotypic and molecular characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Ghana. Ann Clin Microbiol Antimicrob. 2020;19(1):1-12.

82.  Bellucci MC, Volonterio A, Molinari H. Aminoglycoside resistance mechanisms: structural insights and therapeutic implications. Curr Opin Struct Biol. 2024;84:102-113.

83.  Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.

84.  Acheampong K, Kwakye-Nuako G, Asante KP, Asmah RH, Boateng R, Gyasi RK. Antimicrobial susceptibility of Salmonella enterica serovar Typhi isolated from patients in Ghana: A ten-year review. BMC Infect Dis. 2019;19(1):676.

85.  Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis. 2012;2012:976273.

86.  Ahmed MO, Clegg PD, Williams NJ, Baptiste KE, Bennett M. Antimicrobial resistance in bacteria isolated from farm animals in the UK: A systematic review. Vet Rec. 2020;186(13):e19.

87.  Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents. 1999;11(2):93-100.

88.  Serwacki J, Klesiewicz K, Michalska A. The use of fluoroquinolones in combating bacterial pathogens: a historical and contemporary perspective. J Chemother. 2023;35(4):250-260.

89.  Lungu I, Chirita I, Radulescu A. Fluoroquinolones: evolution, spectrum of activity, and clinical applications. Rev Chim (Bucharest). 2022;73(10):2400-2410.

90.  Wang J, Yin Y, Wang C, et al. The mechanism of nitrofurantoin-induced organ toxicity: a review of current literature. Chem Biol Interact. 2008;175(1-3):23-29.

91.  Paranos A, Pešaković M, Mićić M. Nitrofurantoin: mechanism of action and resistance. J Chem. 2022;2022:1-12.

92.  McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and clinical effectiveness in the context of antimicrobial resistance. Diagn Microbiol Infect Dis. 1994;19(1):21-27.

93.  Andersson MI. Development of the quinolones. J Antimicrob Chemother. 2003;51(suppl 1):1-11.

94.  Cunha BA. Antibiotic side effects. Med Clin North Am. 2001;85(1):149-185.

95.  Cui N, Bian X. Fluoroquinolone-associated tendinopathy: a systematic review. J Clin Pharm Ther. 2021;46(4):927-939.

96.  Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.

97.  Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents. 1999;11(2):93-100.

98.  Serwacki J, Klesiewicz K, Michalska A. The use of fluoroquinolones in combating bacterial pathogens: a historical and contemporary perspective. J Chemother. 2023;35(4):250-260.

99.  Lungu I, Chirita I, Radulescu A. Fluoroquinolones: evolution, spectrum of activity, and clinical applications. Rev Chim (Bucharest). 2022;73(10):2400-2410.

100. Wang J, Yin Y, Wang C, et al. The mechanism of nitrofurantoin-induced organ toxicity: a review of current literature. Chem Biol Interact. 2008;175(1-3):23-29.

101. Paranos A, Pešaković M, Mićić M. Nitrofurantoin: mechanism of action and resistance. J Chem. 2022;2022:1-12.

102. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and clinical effectiveness in the context of antimicrobial resistance. Diagn Microbiol Infect Dis. 1994;19(1):21-27.

103. Andersson MI. Development of the quinolones. J Antimicrob Chemother. 2003;51(suppl 1):1-11.

104. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):2155-2164.

105. Cunha B. Nitrofurantoin: mechanisms of action and drug interactions. J Med. 1989;20(3-4):287-295.

106. Cunha BA. Antibiotic side effects. Med Clin North Am. 2001;85(1):149-185.

107. Cui N, Bian X. Fluoroquinolone-associated tendinopathy: a systematic review. J Clin Pharm Ther. 2021;46(4):927-939.

108. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.

109. Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents. 1999;11(2):93-100.

110. Serwacki J, Klesiewicz K, Michalska A. The use of fluoroquinolones in combating bacterial pathogens: a historical and contemporary perspective. J Chemother. 2023;35(4):250-260.

111. Lungu I, Chirita I, Radulescu A. Fluoroquinolones: evolution, spectrum of activity, and clinical applications. Rev Chim (Bucharest). 2022;73(10):2400-2410.

112. Wang J, Yin Y, Wang C, et al. The mechanism of nitrofurantoin-induced organ toxicity: a review of current literature. Chem Biol Interact. 2008;175(1-3):23-29.

113. Paranos A, Pešaković M, Mićić M. Nitrofurantoin: mechanism of action and resistance. J Chem. 2022;2022:1-12.

114. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and clinical effectiveness in the context of antimicrobial resistance. Diagn Microbiol Infect Dis. 1994;19(1):21-27.

115. Andersson MI. Development of the quinolones. J Antimicrob Chemother. 2003;51(suppl 1):1-11.

116. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):2155-2164.

117. Cunha B. Nitrofurantoin: mechanisms of action and drug interactions. J Med. 1989;20(3-4):287-295.

118. Cunha BA. Antibiotic side effects. Med Clin North Am. 2001;85(1):149-185.

119. Cui N, Bian X. Fluoroquinolone-associated tendinopathy: a systematic review. J Clin Pharm Ther. 2021;46(4):927-939.

120. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.

121. Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn P. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents. 1999;11(2):93-100.

122. Serwacki J, Klesiewicz K, Michalska A. The use of fluoroquinolones in combating bacterial pathogens: a historical and contemporary perspective. J Chemother. 2023;35(4):250-260.

123. Lungu I, Chirita I, Radulescu A. Fluoroquinolones: evolution, spectrum of activity, and clinical applications. Rev Chim (Bucharest). 2022;73(10):2400-2410.

124. Wang J, Yin Y, Wang C, et al. The mechanism of nitrofurantoin-induced organ toxicity: a review of current literature. Chem Biol Interact. 2008;175(1-3):23-29.

125. Paranos A, Pešaković M, Mićić M. Nitrofurantoin: mechanism of action and resistance. J Chem. 2022;2022:1-12.

126. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and clinical effectiveness in the context of antimicrobial resistance. Diagn Microbiol Infect Dis. 1994;19(1):21-27.

127. Andersson MI. Development of the quinolones. J Antimicrob Chemother. 2003;51(suppl 1):1-11.

128. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):2155-2164.

129. Cunha B. Nitrofurantoin: mechanisms of action and drug interactions. J Med. 1989;20(3-4):287-295.

130. Cunha BA. Antibiotic side effects. Med Clin North Am. 2001;85(1):149-185.

131. Cui N, Bian X. Fluoroquinolone-associated tendinopathy: a systematic review. J Clin Pharm Ther. 2021;46(4):927-939.

132. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.

133. Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents. 1999;11(2):93-100.

134. Serwacki J, Klesiewicz K, Michalska A. The use of fluoroquinolones in combating bacterial pathogens: a historical and contemporary perspective. J Chemother. 2023;35(4):250-260.

135. Lungu I, Chirita I, Radulescu A. Fluoroquinolones: evolution, spectrum of activity, and clinical applications. Rev Chim (Bucharest). 2022;73(10):2400-2410.

136. Wang J, Yin Y, Wang C, et al. The mechanism of nitrofurantoin-induced organ toxicity: a review of current literature. Chem Biol Interact. 2008;175(1-3):23-29.

137. Paranos A, Pešaković M, Mićić M. Nitrofurantoin: mechanism of action and resistance. J Chem. 2022;2022:1-12.

138. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and clinical effectiveness in the context of antimicrobial resistance. Diagn Microbiol Infect Dis. 1994;19(1):21-27.

139. Andersson MI. Development of the quinolones. J Antimicrob Chemother. 2003;51(suppl 1):1-11.

140. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):2155-2164.

141.  Dunne, S., Shannon, B., Dunne, C., & Cullen, W. (2022). A review of antibiotic use in urinary tract infections in primary care and emergency departments. Antibiotics, 11(7), 890.

142. Zhai, R., Ding, X., Li, H., Yang, L., Zhao, L., & Zhang, F. (2023). Aminoglycoside resistance mechanisms: enzymatic modification and efflux pumps. Microbiology Spectrum, 11(1), e04499-22.

143. Zahra, R. (2021). Carbapenems: a comprehensive review of their classification, mechanisms of action and resistance. Journal of Applied Pharmaceutical Science, 11(2), 001-012.

144. Zamudio, R., Benavides, J. A., Bromfield, E. S., Labuschagne, N., & Towner, K. J. (2022). Cephalosporin resistance mechanisms in Gram-negative bacteria: global patterns and clinical implications. Antimicrobial Resistance & Infection Control, 11(1), 45.